Miconazole - Tibotec

Drug Profile

Miconazole - Tibotec

Alternative Names: Tibozole

Latest Information Update: 09 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tibotec Pharmaceuticals
  • Developer Janssen Therapeutics; RHEI Pharmaceuticals
  • Class Antifungals; Imidazoles; Small molecules
  • Mechanism of Action Cell membrane modulators; Cholesterol synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Oropharyngeal candidiasis

Most Recent Events

  • 09 Apr 2015 Miconazole is approved and is in phase-III development for Oropharyngeal candidiasis in Ukraine, Africa and China, respectively
  • 27 Aug 2012 Phase III development is ongoing in China
  • 09 Dec 2008 Phase-III clinical trials in Oropharyngeal candidiasis in China (Buccal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top